511 related articles for article (PubMed ID: 31073788)
1. Cardiotoxicity of Contemporary Breast Cancer Treatments.
Lee Chuy K; Yu AF
Curr Treat Options Oncol; 2019 May; 20(6):51. PubMed ID: 31073788
[TBL] [Abstract][Full Text] [Related]
2. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
3. Strategies to Prevent Cardiotoxicity.
Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
[TBL] [Abstract][Full Text] [Related]
4. Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention.
Narayan V; Ky B
Annu Rev Med; 2018 Jan; 69():97-111. PubMed ID: 29414258
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.
Menna P; Minotti G; Salvatorelli E
Curr Cardiol Rep; 2019 Mar; 21(5):33. PubMed ID: 30887161
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
[TBL] [Abstract][Full Text] [Related]
7. Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study.
Skitch A; Mital S; Mertens L; Liu P; Kantor P; Grosse-Wortmann L; Manlhiot C; Greenberg M; Nathan PC
BMC Cancer; 2017 Aug; 17(1):519. PubMed ID: 28774277
[TBL] [Abstract][Full Text] [Related]
8. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.
Virani SA; Dent S; Brezden-Masley C; Clarke B; Davis MK; Jassal DS; Johnson C; Lemieux J; Paterson I; Sebag IA; Simmons C; Sulpher J; Thain K; Thavendiranathan P; Wentzell JR; Wurtele N; Côté MA; Fine NM; Haddad H; Hayley BD; Hopkins S; Joy AA; Rayson D; Stadnick E; Straatman L
Can J Cardiol; 2016 Jul; 32(7):831-41. PubMed ID: 27343741
[TBL] [Abstract][Full Text] [Related]
9. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
[TBL] [Abstract][Full Text] [Related]
10. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This?
Caron J; Nohria A
Curr Oncol Rep; 2018 Jun; 20(8):61. PubMed ID: 29876677
[TBL] [Abstract][Full Text] [Related]
12. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Denlinger CS; Sanft T; Baker KS; Broderick G; Demark-Wahnefried W; Friedman DL; Goldman M; Hudson M; Khakpour N; King A; Koura D; Lally RM; Langbaum TS; McDonough AL; Melisko M; Montoya JG; Mooney K; Moslehi JJ; O'Connor T; Overholser L; Paskett ED; Peppercorn J; Pirl W; Rodriguez MA; Ruddy KJ; Silverman P; Smith S; Syrjala KL; Tevaarwerk A; Urba SG; Wakabayashi MT; Zee P; McMillian NR; Freedman-Cass DA
J Natl Compr Canc Netw; 2018 Oct; 16(10):1216-1247. PubMed ID: 30323092
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies - Part 2.
Manolis AA; Manolis TA; Mikhailidis DP; Manolis AS
Expert Opin Drug Saf; 2018 Sep; 17(9):893-915. PubMed ID: 30126303
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced cardiomyopathy.
Higgins AY; O'Halloran TD; Chang JD
Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
[TBL] [Abstract][Full Text] [Related]
15. Organization and implementation of a cardio-oncology program.
Fiuza M; Ribeiro L; Magalhães A; Sousa AR; Nobre Menezes M; Jorge M; Costa L; Pinto FJ
Rev Port Cardiol; 2016 Sep; 35(9):485-94. PubMed ID: 27503589
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
Levis BE; Binkley PF; Shapiro CL
Lancet Oncol; 2017 Aug; 18(8):e445-e456. PubMed ID: 28759384
[TBL] [Abstract][Full Text] [Related]
17. The cancer patient and cardiology.
Zamorano JL; Gottfridsson C; Asteggiano R; Atar D; Badimon L; Bax JJ; Cardinale D; Cardone A; Feijen EAM; Ferdinandy P; López-Fernández T; Gale CP; Maduro JH; Moslehi J; Omland T; Plana Gomez JC; Scott J; Suter TM; Minotti G
Eur J Heart Fail; 2020 Dec; 22(12):2290-2309. PubMed ID: 32809231
[TBL] [Abstract][Full Text] [Related]
18. Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies.
Vakilpour A; Lefebvre B; Lai C; Scherrer-Crosbie M
Blood Rev; 2024 Mar; 64():101166. PubMed ID: 38182490
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular sequelae of breast cancer treatments: A review.
Babak S; Brezden-Masley C
Curr Probl Cancer; 2018 Jul; 42(4):409-421. PubMed ID: 30195806
[No Abstract] [Full Text] [Related]
20. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
